TEL AVIV, Israel, June 4, 2014 (GLOBE NEWSWIRE) -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that recently published data in the April 2014 issue of Biochimie supports the importance of the regulation of ABCA1-induced reverse cholesterol transport on the pathogenesis of Non-Alcoholic Steato-Hepatitis, or NASH.
Help employers find you! Check out all the jobs and post your resume.
